Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on May 6th, 2023%
Technology intelligence company CB Insights says this week that psychedelic therapies and services are generating little interest among venture investors this year, with only nine deals totaling $21 million. . . . → Read More: Infographic – Psychedelics Funding Coming Down
By Alan, on May 5th, 2023%
New research with lab animals shows gene-edited viruses can target and remove harmful E. coli bacteria from the gut, including strains usually resistant to antibiotics. . . . → Read More: Crispr Therapy Shown to Remove E. Coli in Gut
By Alan, on May 4th, 2023%
The first participant in a clinical trial received a dose of a psychedelic therapy, assessing the experimental compound in people with treatment resistant depression. . . . → Read More: Trial Underway Testing Psychedelic Drug for Depression
By Alan, on May 1st, 2023%
A new company that says it can stop disease-causing proteins from forming in cells began public operations today, and is raising $75 million in its first venture round. . . . → Read More: Biotech to Design Disease-Blocking Drugs, Gains $75M
By Alan, on April 28th, 2023%
A clinical trial shows a light-activated protein from an injected gene improves visual abilities in people with advanced retinitis pigmentosa, an inherited eye disorder. . . . → Read More: Light-Activated Therapy Improves Vision in Inherited Disease Trial
By Alan, on April 27th, 2023%
Ultra-low quantities of an experimental Covid-19 protein vaccine delivered in synthetic cell components are shown in lab animals to generate strong immune responses. . . . → Read More: Low-Dose Covid-19 Vaccine Generates Strong Immune Response
By Alan, on April 26th, 2023%
A study of insurance claims records matching the design of randomized clinical trials shows claims data can in some cases resemble clinical trial results to make causal inferences. . . . → Read More: Real World Evidence Shown to Emulate Some Clinical Trials
By Alan, on April 20th, 2023%
First results of a clinical trial show a drug derived from plants to aid in smoking cessation helps cut the use of e-cigarettes among non-smokers of burning tobacco. . . . → Read More: Trial Shows Plant-Based Drug Helps Reduce Vaping
By Alan, on April 11th, 2023%
A start-up company with a process for harvesting large quantities of cells that infiltrate and kill solid tumors is raising $10 million in seed venture funds. . . . → Read More: Cancer Cell Therapy Biotech Launches, Raises $10M
By Alan, on April 10th, 2023%
A biotechnology industry group calls Friday’s ruling in a Federal district court to suspend approval of the drug mifepristone “an assault on science.” . . . → Read More: Biotech Group Blasts Reproductive Drug Ruling
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|